Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Mesoblast (MESO)

Mesoblast Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MESO
DateTimeSourceHeadlineSymbolCompany
07/03/202502:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
06/03/202523:54GlobeNewswire Inc.Mesoblast Added to S&P/ASX 200 INDEXNASDAQ:MESOMesoblast Limited
27/02/202522:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
26/02/202522:30GlobeNewswire Inc.Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This QuarterNASDAQ:MESOMesoblast Limited
25/02/202523:13GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
23/02/202523:33GlobeNewswire Inc.Dr. Gregory George MD PhD Joins Mesoblast BoardNASDAQ:MESOMesoblast Limited
13/02/202523:37GlobeNewswire Inc.Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation MeetingsNASDAQ:MESOMesoblast Limited
13/02/202505:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MESOMesoblast Limited
12/02/202521:04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MESOMesoblast Limited
06/02/202520:05Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MESOMesoblast Limited
05/02/202520:59Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
31/01/202500:11GlobeNewswire Inc.Ryoncil® Commercial Launch Update and Product PipelineNASDAQ:MESOMesoblast Limited
30/01/202523:20GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024NASDAQ:MESOMesoblast Limited
19/12/202400:08GlobeNewswire Inc.Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyNASDAQ:MESOMesoblast Limited
18/12/202412:30GlobeNewswire Inc.Mesoblast to be Added to Nasdaq Biotechnology IndexNASDAQ:MESOMesoblast Limited
13/12/202421:04Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
09/12/202421:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
04/12/202423:32GlobeNewswire Inc.FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
02/12/202423:20GlobeNewswire Inc.Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationNASDAQ:MESOMesoblast Limited
18/11/202411:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
30/10/202423:11GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024NASDAQ:MESOMesoblast Limited
09/10/202419:42Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MESOMesoblast Limited
30/09/202400:55GlobeNewswire Inc.Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product LaunchNASDAQ:MESOMesoblast Limited
29/08/202411:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
28/08/202423:27GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024NASDAQ:MESOMesoblast Limited
27/08/202423:25GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
31/07/202401:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024NASDAQ:MESOMesoblast Limited
23/07/202411:53GlobeNewswire Inc.FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
22/07/202400:45GlobeNewswire Inc.Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainNASDAQ:MESOMesoblast Limited
09/07/202400:37GlobeNewswire Inc.Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

Your Recent History